USA/Brazilië: Behandeling leverkanker met zeer zwakke elektromagnetische velden.
dinsdag, 16 augustus 2011 - Categorie: Onderzoeken
Gerelateerd artikel: Berichten%20Internationaal/5991
Bron: British Journal of Cancer 9 August 2011; doi: 10.1038/bjc.2011.292
Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields
F P Costa 1, A C de Oliveira 1, R Meirelles 1, M C C Machado 1, T Zanesco 1, R Surjan 1,
M C Chammas 2, M de Souza Rocha 2,
D Morgan 3,
A Cantor 4,
J Zimmerman 5,
I Brezovich 6,
N Kuster 7,
A Barbault 8 and
B Pasche 5
Department of Transplantation and Liver Surgery, Hospital das Clínicas da Faculdade de Medicina, University of São Paulo, Av. Dr. Enéas de Carvalho Aguiar, 255, São Paulo 05403-000, Brazil
Department of Radiology, Hospital das Clínicas, University of São Paulo, São Paulo 05403-000, Brazil
Department of Radiology, University of Alabama at Birmingham and UAB Comprehensive Cancer Center, Birmingham, AL 35294, USA
Biostatistics and Bioinformatics Shared Facility, University of Alabama at Birmingham and UAB Comprehensive Cancer Center, Birmingham, AL 35294, USA
Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham and UAB Comprehensive Cancer Center, 1802 6th Ave South, NP 2566, Birmingham, AL 35294-3300, USA
Department of Radiation Oncology, The University of Alabama at Birmingham and UAB Comprehensive Cancer Center, Birmingham, AL 35294, USA
IT'IS Foundation, Swiss Federal Institute of Technology, Zurich, Switzerland
Rue de Verdun 20, Colmar 68000, France
Dr FP Costa, E-mail: firstname.lastname@example.org;
Dr B Pasche, E-mail: Boris.Pasche@ccc.uab.edu
Therapeutic options for patients with advanced hepatocellular carcinoma (HCC) are limited. There is emerging evidence that the growth of cancer cells may be altered by very low levels of electromagnetic fields modulated at specific frequencies.
A single-group, open-label, phase I/II study was performed to assess the safety and effectiveness of the intrabuccal administration of very low levels of electromagnetic fields amplitude modulated at HCC-specific frequencies in 41 patients with advanced HCC and limited therapeutic options. Three-daily 60-min outpatient treatments were administered until disease progression or death. Imaging studies were performed every 8 weeks. The primary efficacy end point was progression-free survival greater than or equal to6 months. Secondary efficacy end points were progression-free survival and overall survival.
Treatment was well tolerated and there were no NCI grade 2, 3 or 4 toxicities. In all, 14 patients (34.1%) had stable disease for more than 6 months. Median progression-free survival was 4.4 months (95% CI 2.1–5.3) and median overall survival was 6.7 months (95% CI 3.0–10.2). There were three partial and one near complete responses.
Treatment with intrabuccally administered amplitude-modulated electromagnetic fields is safe, well tolerated, and shows evidence of antitumour effects in patients with advanced HCC.
Voor het originele abstract zie:
Lees verder in de categorie Onderzoeken | Terug naar homepage | Lees de introductie